Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does Directly Acting Antivirals Usage Affect HCV Related Hepatocellular Carcinoma Recurrence After Percutaneous Ablation: A Randomized Controlled Trial

NCT04653818 is registered in ClinicalTrials.gov with Alexandria University as lead sponsor.

NCT NCT04653818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04653818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does Directly Acting Antivirals Usage Affect HCV Related Hepatocellular Carcinoma Recurrence After Percutaneous Ablation: A Randomized Controlled Trial
Lead sponsor
Alexandria University
Phase
Phase 4
Overall status
Completed
Start date
October 5, 2020
Completion date
October 24, 2022
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, hepatocellular carcinoma, neoplasm recurrence, treatment complication